TGM2 and posterior cortical atrophy: In addition, we analyzed the expression of TGM2 in prostatic tumoral sections of 56 treatment-naïve patients with PCa who had undergone radical prostatectomy (Fig. 6J) and found that patients expressing high levels of TGM2 had lower progression-free survival (PFS) (Fig. 6K), with the average PFS shortened by 17 months compared to those expressing low TGM2 levels (table S13).